CB2 Cannabinoid Receptor

12/19/2005 - "The identification of peripherally expressed CB2 receptors and reports that the selective activation of cannabinoid CB2 receptors produces antinociception without traditional cannabinergic side effects suggests that selective cannabinoid CB2 receptor agonists might be useful in the management of pain. "
03/26/2015 - "The CB2 receptor has been considered as an inspiring drug target for the treatment of pain and immune-related diseases. "
01/01/2013 - "These data provide new clinically relevant evidence that joint damage and spinal CB2 receptor expression are correlated combined with converging pre-clinical evidence that activation of CB2 receptors inhibits central sensitization and its contribution to the manifestation of chronic OA pain. "
01/01/2013 - "Systemic administration of JWH133 attenuated these markers of central sensitization, providing a neurobiological basis for analgesic effects of the CB2 receptor in this model of OA pain. "
02/17/2012 - "Agonists for the cannabinoid CB2 receptor are antinociceptive in several rodent models and several reports have suggested that the target for these drugs is CB2 expressed in the spinal cord pain pathway. "

10/01/2013 - "Cannabinoid-1 (CB1) and cannabinoid-2 (CB2) receptor expression is related to survival in several types of cancer, and the aim of this study was to find out whether the expression of CB1 and CB2 receptors is associated with survival in primary SCC of the head and neck. "
03/15/2010 - "This study was designed to develop new radioligands for imaging of CB2 receptor in cancer using biomedical imaging technique positron emission tomography (PET). "
07/01/2011 - "These effects were accompanied by an increase in CB2 receptor protein in plantar skin of the tumor-bearing paw as well as an increase in the level of 2-AG. "
01/01/2010 - "We also found that 91% of ErbB2-positive tumors express the non-psychotropic cannabinoid receptor CB2. "
06/02/2014 - "Cannabinoid CB2 receptor as a new phototherapy target for the inhibition of tumor growth."

04/01/2015 - "Concomitant administration of small doses of CB1 and/or CB2 receptor agonists and COX-2 or NOS inhibitors can be effective in the alleviation of diabetic neuropathic pain."
01/01/2014 - "Overall, our work shows that NMP-7 mediates a significant analgesic effect in a model of persistent inflammatory and chronic neuropathic pain by way of T-type channel modulation and CB2 receptor activation. "
10/10/2013 - "These results indicate that spinal cannabinoid systems are changed in diabetic mice and suggest that cannabinoid CB2 receptor agonists might have an ability to recover diabetic neuropathic pain."
11/01/2007 - "Both CB1 and CB2 receptor agonists have analgesic effects in a range of models of inflammatory and neuropathic pain. "
05/31/2007 - "Selective CB2 receptor agonists are promising potential therapeutic agents for the treatment of inflammatory and neuropathic pain. "

01/01/2010 - "In conclusion, we show that selective CB2 receptor stimulation prevents thermal hyperalgesia, alleviates mechanical allodynia and facilitates the proliferation of anti-inflammatory microglial phenotype in the ipsilateral dorsal horn of the spinal cord in SNI mice."
03/31/2008 - "We sought to examine the involvement of central cannabinoid CB2 receptor activation in modulating mechanical allodynia in a mouse model of neuropathic pain. "
03/31/2008 - "Involvement of central cannabinoid CB2 receptor in reducing mechanical allodynia in a mouse model of neuropathic pain."
10/01/2006 - "In contrast, the CB1, but not the CB2, receptor antagonist enhanced colitis-induced hyperalgesia. "
10/01/2003 - "Local, peripheral CB2 receptor activation inhibits inflammation and inflammatory hyperalgesia. "

07/01/2015 - "Interestingly, the increase in CB2 receptor expression in the inflammation-driven model was significantly more pronounced than that in the neurotoxic model. "
02/12/2015 - "The CB2 cannabinoid receptor has been implicated in the regulation of intestinal inflammation. "
01/01/2013 - "Their effects are mostly mediated through CB1 and CB2 receptor-dependent modulation of excitotoxicity, inflammation, oxidative stress, and other processes. "
01/01/2008 - "The effect of acute and chronic joint inflammation on CB2 receptor-mediated responses was also tested. "
11/01/2007 - "CB2 receptor activation acts mostly via immune cells to reduce inflammation. "